• +1-646-491-9876
    • +91-20-67278686

    Search

    Chronic Lymphocytic Leukemia-Pipeline Review H1 2017

    Chronic Lymphocytic Leukemia-Pipeline Review H1 2017

    • Report Code ID: RW0001834364
    • Category Pharmaceuticals
    • No. of Pages 791
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2017, provides an overview of the Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline landscape.

    Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from white blood cells (called lymphocytes) in the bone marrow. It then invades the blood. Symptoms usually develop slowly. Symptoms of CLL include abnormal bruising (if platelets are low) , fever, infections that keep coming back (recur) , loss of appetite or becoming full too quickly (early satiety) and weight loss. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 44, 51, 1, 3, 53, 12 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 7, 10 and 7 molecules, respectively.

    Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL) (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    Introduction 7
    Chronic Lymphocytic Leukemia (CLL) - Overview 8
    Chronic Lymphocytic Leukemia (CLL) - Therapeutics Development 9
    Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 35
    Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 51
    Chronic Lymphocytic Leukemia (CLL) - Drug Profiles 102
    Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 748
    Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 756
    Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 758
    Appendix 770

    List of Tables

    Number of Products under Development for Chronic Lymphocytic Leukemia (CLL) , H1 2017 29
    Number of Products under Development by Companies, H1 2017 31
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 32
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017 33
    Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017 34
    Number of Products under Development by Companies, H1 2017 (Contd..4) , H1 2017 35
    Number of Products under Development by Companies, H1 2017 (Contd..5) , H1 2017 36
    Number of Products under Development by Companies, H1 2017 (Contd..6) , H1 2017 37
    Number of Products under Development by Universities/Institutes, H1 2017 38
    Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017 39
    Products under Development by Companies, H1 2017 40
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 41
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017 42
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017 43
    Products under Development by Companies, H1 2017 (Contd..4) , H1 2017 44
    Products under Development by Companies, H1 2017 (Contd..5) , H1 2017 45
    Products under Development by Companies, H1 2017 (Contd..6) , H1 2017 46
    Products under Development by Companies, H1 2017 (Contd..7) , H1 2017 47
    Products under Development by Companies, H1 2017 (Contd..8) , H1 2017 48
    Products under Development by Companies, H1 2017 (Contd..9) , H1 2017 49
    Products under Development by Companies, H1 2017 (Contd..10) , H1 2017 50
    Products under Development by Companies, H1 2017 (Contd..11) , H1 2017 51
    Products under Development by Universities/Institutes, H1 2017 52
    Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017 54
    Number of Products by Stage and Target, H1 2017 56
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017 57
    Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017 58
    Number of Products by Stage and Target, H1 2017 (Contd..3) , H1 2017 59
    Number of Products by Stage and Target, H1 2017 (Contd..4) , H1 2017 60
    Number of Products by Stage and Mechanism of Action, H1 2017 62
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017 63
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017 64
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3) , H1 2017 65
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4) , H1 2017 66
    Number of Products by Stage and Route of Administration, H1 2017 68
    Number of Products by Stage and Molecule Type, H1 2017 70
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H1 2017 71
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc, H1 2017 72
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by ABL Bio Inc, H1 2017 72
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by ACEA Biosciences Inc, H1 2017 73
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by ADC Therapeutics Sarl, H1 2017 73
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aeglea BioTherapeutics Inc, H1 2017 74
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Altor BioScience Corp, H1 2017 74
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Alvotech Iceland, H1 2017 75
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Amgen Inc, H1 2017 75
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aptevo Therapeutics Inc, H1 2017 76
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aptose Biosciences Inc, H1 2017 76
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Arno Therapeutics Inc, H1 2017 77
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by ArQule Inc, H1 2017 77
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc, H1 2017 78
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals Inc, H1 2017 78
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bayer AG, H1 2017 79
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by BeiGene Ltd, H1 2017 79
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bellicum Pharmaceuticals Inc, H1 2017 80
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bionomics Ltd, H1 2017 80
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bionovis SA, H1 2017 81
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Biothera Pharmaceutical Inc, H1 2017 81
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H1 2017 82
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Company, H1 2017 82
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corp, H1 2017 83
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellectar Biosciences Inc, H1 2017 84
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celltrion Inc, H1 2017 84
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellular Biomedicine Group Inc, H1 2017 85
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Coherus BioSciences Inc, H1 2017 85
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017 86
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Debiopharm International SA, H1 2017 86
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Deciphera Pharmaceuticals LLC, H1 2017 87
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Eli Lilly and Company, H1 2017 87
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 88
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by GeneaMed Ltd, H1 2017 88
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Genentech Inc, H1 2017 89
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Gilead Sciences Inc, H1 2017 89
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Grupo Ferrer Internacional SA, H1 2017 90
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Heidelberg Pharma GmbH, H1 2017 90
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Humorigin Biotechnology Corp, H1 2017 90
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hutchison China MediTech Ltd, H1 2017 91
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hybrigenics SA, H1 2017 91
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Igenica Biotherapeutics Inc, H1 2017 92
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immatics Biotechnologies GmbH, H1 2017 92
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics Inc, H1 2017 93
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Incyte Corp, H1 2017 94
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Inflection Biosciences Ltd, H1 2017 94
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innate Pharma SA, H1 2017 95
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innovent Biologics Inc, H1 2017 95
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Johnson & Johnson, H1 2017 96
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Juno Therapeutics Inc, H1 2017 96
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kancera AB, H1 2017 97
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Karyopharm Therapeutics Inc, H1 2017 98
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kite Pharma Inc, H1 2017 98
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Les Laboratoires Servier SAS, H1 2017 99
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by LFB SA, H1 2017 99
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ligand Pharmaceuticals Inc, H1 2017 100
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lymphocyte Activation Technologies SA, H1 2017 100
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Medicenna Therapeutics Corp, H1 2017 101
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by MENTRIK Biotech LLC, H1 2017 101
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Merck & Co Inc, H1 2017 102
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Merck KGaA, H1 2017 102
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Mesoblast Ltd, H1 2017 103
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Millennium Pharmaceuticals Inc, H1 2017 103
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by MorphoSys AG, H1 2017 104
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by NantKwest Inc, H1 2017 104
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Novartis AG, H1 2017 105
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Oncternal Therapeutics Inc, H1 2017 106
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017 107
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by PEP-Therapy SAS, H1 2017 107
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Pfizer Inc, H1 2017 108
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by PIQUR Therapeutics AG, H1 2017 108
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Plexxikon Inc, H1 2017 109
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Portola Pharmaceuticals Inc, H1 2017 109
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Qurient Co Ltd, H1 2017 110
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Redx Pharma Plc, H1 2017 110
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Respiratorius AB, H1 2017 111
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Rhizen Pharmaceuticals SA, H1 2017 111
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sandoz International GmbH, H1 2017 112
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sanofi, H1 2017 112
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Selvita SA, H1 2017 113
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Simcere Pharmaceutical Group, H1 2017 113
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sorrento Therapeutics Inc, H1 2017 114
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Supratek Pharma Inc, H1 2017 114
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Targazyme Inc, H1 2017 115
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by TG Therapeutics Inc, H1 2017 115
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tolero Pharmaceuticals Inc, H1 2017 116
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by TRACON Pharmaceuticals Inc, H1 2017 116
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tragara Pharmaceuticals Inc, H1 2017 117
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Trillium Therapeutics Inc, H1 2017 117
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by United BioPharma Inc, H1 2017 118
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Unum Therapeutics Inc, H1 2017 118
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Verastem Inc, H1 2017 119
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Viralytics Ltd, H1 2017 119
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Xencor Inc, H1 2017 120
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by ZIOPHARM Oncology Inc, H1 2017 120
    Chronic Lymphocytic Leukemia (CLL) - Pipeline by Zymeworks Inc, H1 2017 121
    Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2017 768
    Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2017 (Contd..1) , H1 2017 769
    Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2017 (Contd..2) , H1 2017 770
    Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2017 (Contd..3) , H1 2017 771
    Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2017 (Contd..4) , H1 2017 772
    Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2017 (Contd..5) , H1 2017 773
    Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2017 (Contd..6) , H1 2017 774
    Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2017 (Contd..7) , H1 2017 775
    Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H1 2017 776
    Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H1 2017 (Contd..1) , H1 2017 777

    List of Figures

    Number of Products under Development for Chronic Lymphocytic Leukemia (CLL) , H1 2017 29
    Number of Products under Development by Companies, H1 2017 30
    Number of Products under Development by Universities/Institutes, H1 2017 38
    Number of Products by Top 10 Targets, H1 2017 55
    Number of Products by Stage and Top 10 Targets, H1 2017 55
    Number of Products by Top 10 Mechanism of Actions, H1 2017 61
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017 61
    Number of Products by Top 10 Routes of Administration, H1 2017 67
    Number of Products by Stage and Top 10 Routes of Administration, H1 2017 67
    Number of Products by Top 10 Molecule Types, H1 2017 69
    Number of Products by Stage and Top 10 Molecule Types, H1 2017 69
    4SC AG
    AbbVie Inc
    ABL Bio Inc
    ACEA Biosciences Inc
    ADC Therapeutics Sarl
    Aeglea BioTherapeutics Inc
    Altor BioScience Corp
    Alvotech Iceland
    Amgen Inc
    Aptevo Therapeutics Inc
    Aptose Biosciences Inc
    Arno Therapeutics Inc
    ArQule Inc
    Astellas Pharma Inc
    Astex Pharmaceuticals Inc
    Bayer AG
    BeiGene Ltd
    Bellicum Pharmaceuticals Inc
    Bionomics Ltd
    Bionovis SA
    Biothera Pharmaceutical Inc
    Boehringer Ingelheim GmbH
    Bristol-Myers Squibb Company
    Celgene Corp
    Cellectar Biosciences Inc
    Celltrion Inc
    Cellular Biomedicine Group Inc
    Coherus BioSciences Inc
    Cyclacel Pharmaceuticals Inc
    Debiopharm International SA
    Deciphera Pharmaceuticals LLC
    Eli Lilly and Company
    F. Hoffmann-La Roche Ltd
    GeneaMed Ltd
    Genentech Inc
    Gilead Sciences Inc
    Grupo Ferrer Internacional SA
    Heidelberg Pharma GmbH
    Humorigin Biotechnology Corp
    Hutchison China MediTech Ltd
    Hybrigenics SA
    Igenica Biotherapeutics Inc
    Immatics Biotechnologies GmbH
    Immunomedics Inc
    Incyte Corp
    Inflection Biosciences Ltd
    Innate Pharma SA
    Innovent Biologics Inc
    Johnson & Johnson
    Juno Therapeutics Inc
    Kancera AB
    Karyopharm Therapeutics Inc
    Kite Pharma Inc
    Les Laboratoires Servier SAS
    LFB SA
    Ligand Pharmaceuticals Inc
    Lymphocyte Activation Technologies SA
    Medicenna Therapeutics Corp
    MENTRIK Biotech LLC
    Merck & Co Inc
    Merck KGaA
    Mesoblast Ltd
    Millennium Pharmaceuticals Inc
    MorphoSys AG
    NantKwest Inc
    Novartis AG
    Oncternal Therapeutics Inc
    Ono Pharmaceutical Co Ltd
    PEP-Therapy SAS
    Pfizer Inc
    PIQUR Therapeutics AG
    Plexxikon Inc
    Portola Pharmaceuticals Inc
    Qurient Co Ltd
    Redx Pharma Plc
    Respiratorius AB
    Rhizen Pharmaceuticals SA
    Sandoz International GmbH
    Sanofi
    Selvita SA
    Simcere Pharmaceutical Group
    Sorrento Therapeutics Inc
    Supratek Pharma Inc
    Targazyme Inc
    TG Therapeutics Inc
    Tolero Pharmaceuticals Inc
    TRACON Pharmaceuticals Inc
    Tragara Pharmaceuticals Inc
    Trillium Therapeutics Inc
    United BioPharma Inc
    Unum Therapeutics Inc
    Verastem Inc
    Viralytics Ltd
    Xencor Inc
    ZIOPHARM Oncology Inc
    Zymeworks Inc

    Request for Sample

    Report Url http://www.reportsweb.com//chronic-lymphocytic-leukemia-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//chronic-lymphocytic-leukemia-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//chronic-lymphocytic-leukemia-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments